Data Highlighting Clinical Efficacy & Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in “Cancer Discovery”

“The survival analyses published today in Cancer Discovery reported that ONC201 frontline treatment, administered post radiation therapy, demonstrated a statistically significant increase in mOS from diagnosis versus historical controls (21.7 months mOS vs. 12 months mOS, p<0.0001). These data are particularly relevant given that enrollment in the ongoing ACTION study occurs in a similar population. Additionally, these data further elucidate the underlying novel mechanism of action for ONC201 in a patient population which has very limited treatment options,” said Mike Andriole, Chief Executive Officer of Chimerix. “While these results require validation in prospectively designed studies, such as the Phase 3 ACTION study, they nevertheless provide ongoing confidence and rationale for ONC201’s monotherapy treatment effect and offer hope to the patients, families and caregivers facing this challenging and life-threatening cancer.”